Medivir abandons hep C NS5A program; Athersys runs into recruitment hurdle; Seattle BioMed wins $16M grant;

@FierceBiotech: ICYMI yesterday: The hottest disease field for biotech startups and M&A might surprise you (not cancer). Article | Follow @FierceBiotech

@JohnCFierce: Two biotechs--Alexion and Regeneron--in top 5 of Forbes' top 100 innovators. Impressive. Article | Follow @JohnCFierce

@RyanMFierce: ICYMI: The man who cured aging? Industry Voices | Follow @RyanMFierce

@EmilyMFierce: Seattle BioMed wins $16M NIH grant for tuberculosis research. Article | Follow @EmilyMFierce

> Medivir ($MVIR), which is partnered with Johnson & Johnson ($JNJ) on the late-stage hep C drug simeprevir, is giving up on its effort to develop an NS5A inhibitor that could be used in an interferon-free cocktail. Release

> Cleveland-based Athersys says it has experienced trouble recruiting patients for a Phase II study of its adult stem cell treatment.  Report

> Seattle BioMed won a $16.6 million grant from the National Institute of Allergy and Infectious Diseases to work on tuberculosis. Story

Medical Device News

@FierceMedDev: Special Report: How did Israel become a hotbed for medical devices? Feature | Follow @FierceMedDev

@DamianFierce: FDA's former IT boss Eric Perakslis nails down industry gig. Story from FierceBiotechIT.com | Follow @DamianFierce

@MarkHFierce: Second Sight achieved the holy grail for new devices: CMS reimbursement. Press release | Follow @MarkHFierce

@MichaelGFierce: St. Jude nets FDA approval for low-radiation ablation catheters. News | Follow @MichaelGFierce

> NxThera to launch U.S. clinical trial with $18.2M Series C. More

> Medtronic closes in on FDA nod with drug-eluting balloon. Article

> Study: Spooked docs are lining Dx companies' pockets. Story

> InSightec's surgery-free brain tech eases tremor in study. Report

Pharma News

@FiercePharma: New data cuts link between preventive use of Propecia/Proscar and faster-growing prostate tumors. More | Follow @FiercePharma

@CarlyHFierce: South Africa's Adcock Ingram so far staying true to suitor CFR - still in exclusive talks after $1.3B bid. Report | Follow @CarlyHFierce

> NY fund trustee to continue push for exec-pay clawbacks at Abbott. Story

> Which are pharma's top 4 innovators? Hint: It's not the big guys. Report

> Novartis opens internal China probe after former rep demanded $800K. News

Pharma Manufacturing News

@EricPFierce: Not all of the Merck plants in Ireland have seen jobs cut. A plant in Swords added 70 people last year. Report | Follow @EricPFierce

> Deaths tied to recalled drugs from Texas compounder. More

> Jubilant HollisterStier adds to global sterile manufacturing supply. Report

> FDA takes deep dive into opioid APIs. More

> Sanofi U.K. plant benefits from SkyePharma progress. Article

> Deaths tied to recalled drugs from Texas compounder. Story

Vaccines News

> Vaccine calms fears of meningitis becoming AIDS-like epidemic. More

> Researchers aim at trial to test whether BCG vaccine cuts risk of allergies. Report

> Study reconfirms safety of flu vaccine in pregnant women. Story

> Researchers aim at trial to test whether BCG vaccine cuts risk of allergies. More

> Incredulity turns to praise as malaria vaccine posts positive PhI data. Article

And Finally… Scientists have discovered 21 mutations that can trigger cancer tumors. Story

Suggested Articles

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.